We are live on
!
Find out more
O
OrbiMed Portfolio holdings
AUM
$5.05B
1-Year Est. Return
125.28%
This Fund
S&P 500
This Quarter
Est. Return
+8.13%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$4.72B
AUM Growth
–
Cap. Flow
+$4.69B
Cap. Flow
% of AUM
99.51%
Top 10 Holdings %
Top 10 Hldgs %
37.69%
Holding
127
New
123
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$272M |
| 2 |
Gilead Sciences
GILD
|
+$251M |
| 3 |
Biogen
BIIB
|
+$219M |
| 4 |
Merck
MRK
|
+$193M |
| 5 |
Viatris
VTRS
|
+$149M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 80.02% |
| 2 | Financials | 2.05% |
| 3 | Technology | 0.14% |
| 4 | Utilities | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Amgen
AMGN
$212B
| $258M | 5.48% |
+2,619,400
| New | +$272M |
|
|
2
Gilead Sciences
GILD
$167B
| $247M | 5.24% |
+4,821,800
| New | +$251M |
|
|
3
Biogen
BIIB
$30.4B
| $221M | 4.68% |
+1,025,800
| New | +$219M |
|
|
4
Merck
MRK
$326B
| $192M | 4.06% |
+4,323,419
| New | +$193M |
|
|
5
Viatris
VTRS
$20.8B
| $155M | 3.28% |
+4,987,000
| New | +$149M |
|
6
Thermo Fisher Scientific
TMO
$214B
| $151M | 3.2% |
+1,786,000
| New | +$149M |
|
7
Bristol-Myers Squibb
BMY
$130B
| $148M | 3.15% |
+3,322,000
| New | +$144M |
|
|
CELG
8
DELISTED
Celgene Corp
CELG
| $145M | 3.07% |
+2,472,800
| New | +$149M |
|
9
Pfizer
PFE
$144B
| $137M | 2.91% |
+5,168,078
| New | +$143M |
|
10
Illumina
ILMN
$29.2B
| $124M | 2.62% |
+1,698,050
| New | +$109M |
|
11
Incyte
INCY
$26B
| $123M | 2.61% |
+5,606,000
| New | +$122M |
|
12
HCA Healthcare
HCA
$92.8B
| $121M | 2.57% |
+3,366,300
| New | +$130M |
|
|
ESRX
13
DELISTED
Express Scripts Holding Company
ESRX
| $118M | 2.5% |
+1,907,170
| New | +$115M |
|
|
ONXX
14
DELISTED
ONYX PHARMACEUTICALS INC
ONXX
| $102M | 2.16% |
+1,175,000
| New | +$108M |
|
15
Elevance Health
ELV
$83.7B
| $97.1M | 2.06% |
+1,187,000
| New | +$88.8M |
|
|
AET
16
DELISTED
Aetna Inc
AET
| $96.5M | 2.05% |
+1,519,000
| New | +$89.2M |
|
|
ICPT
17
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $96.4M | 2.04% |
+2,150,634
| New | +$73.5M |
|
18
Insulet
PODD
$11.6B
| $95.8M | 2.03% |
+3,048,500
| New | +$86.4M |
|
|
19
CALL
Pfizer
PFE
$144B
| $90.7M | 1.92% |
+3,412,852
| New | +$94.3M |
|
|
AGN
20
DELISTED
Allergan plc
AGN
| $82.4M | 1.75% |
+653,200
| New | +$74M |
|
21
Agilent Technologies
A
$39.7B
| $79.3M | 1.68% |
+2,591,892
| New | +$80.5M |
|
22
UnitedHealth
UNH
$389B
| $79.1M | 1.68% |
+1,208,000
| New | +$75.2M |
|
23
Regeneron Pharmaceuticals
REGN
$72.9B
| $79M | 1.67% |
+351,100
| New | +$81.8M |
|
24
BioMarin Pharmaceuticals
BMRN
$12B
| $74.8M | 1.58% |
+1,341,200
| New | +$83.6M |
|
25
AbbVie
ABBV
$465B
| $73.5M | 1.56% |
+1,777,000
| New | +$77.7M |
|
Similar funds
HSA
LIM
NL
BPWM
LFG
JIM
CTC
PAMP
OrbiMed's Q2 2013 Portfolio in Review
Q2 2013 is the first quarter with a 13F filing on record for OrbiMed, which disclosed 127 positions worth $4.72B. Its ten largest holdings account for 38% of the portfolio.
Its largest position is Amgen: 2,619,400 shares worth $258M.
By sector, the portfolio is most concentrated in Healthcare at 80% of assets, followed by Financials and Technology.
- OrbiMed's largest Q2 2013 buy was Amgen: 2,619,400 shares worth $258M.
- OrbiMed's ten largest holdings make up 38% of its $4.72B portfolio in Q2 2013.
- OrbiMed disclosed 127 positions in Q2 2013, its first 13F filing on record.
Based on OrbiMed's 13F filing for Q2 2013, filed 14 Aug 2013.